



Dexycu™ (dexamethasone intraocular suspension) – New drug approval

- On February 9, 2018, the [FDA approved Icon Bioscience's Dexycu \(dexamethasone intraocular suspension\)](#), for the treatment of postoperative inflammation.
- In the U.S., over 4 million cataract surgeries are performed per year.
- Dexycu is the first long-acting intraocular product approved to treat inflammation after cataract surgery.
- The efficacy of Dexycu was demonstrated in a placebo-controlled study enrolling 394 patients. Patients received an intraocular dose of 517 mcg, 342 mcg, or placebo administered by a physician at the end of surgery. The primary endpoint was the proportion of patients with anterior chamber cell clearing on postoperative day 8.
 - The percentage of patients meeting the primary endpoint was 20% in the placebo group, and 57% (difference: 37% [97.5% CI: 24%, 50%]) and 60% (difference: 40% [97.5% CI: 27%, 54%]) in the 342 and 517 mcg treatment groups, respectively.
 - In addition, the percentage of patients receiving rescue medication of ocular steroid or a nonsteroidal antiinflammatory drug was significantly lower at day 3, 8, 15 and 30 in the 342 and 517 mcg treatment groups vs. placebo.
- Warnings and precautions of Dexycu include increase in intraocular pressure, delayed healing, exacerbation of infection, and cataract progression.
- The most common adverse reactions (5 - 15%) reported with Dexycu use were increased intraocular pressure, corneal edema and iritis.
- The recommended dosage of Dexycu is 0.005 mL of dexamethasone 9% (equivalent to 517 mcg) administered as a single dose, intraocularly in the posterior chamber at the end of surgery.
- Icon Bioscience's launch plans for Dexycu are pending. Dexycu will be available as a 9% intraocular suspension equivalent to dexamethasone 103.4 mg/mL in a single-dose vial provided in a kit.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.